New award for pregabalin capsules with sciegen pharmaceuticals. Ordering period is march 2, 2026 to march 1, 2027, with four one-year options.

Active Indefinite Delivery Contract Awarded Last action

Contract number
36E79726D0006
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 68% complete
IDV ceiling
$14,500,887.25
Award type
Single award
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 4 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite-delivery contract to Sciegen Pharmaceuticals Inc. for the supply of Pregabalin Capsules with a ceiling of $14,500,887.25 on March 2, 2026.

The contract covers Pregabalin Capsule dosages ranging from 25 mg to 300 mg in packaging configurations of 90 and 500 capsules per bottle, supplied to multiple federal agencies including the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. Products are distributed through VA and DoD Pharmaceutical Prime Vendor Programs. The contract requires products with unique NDC numbers and exclusive labeling. Packaging specifications include safety-cap configurations, cylindrical bottles with minimum 120 cc volume and 5.75 inch circumference, and bottles capable of accommodating labels measuring 5.25 inches by 2 inches.

The ordering period runs from March 2, 2026 to March 1, 2027, with four one-year options extending the potential term to five years. Place of performance aligns with pharmaceutical distribution to the named federal agencies nationwide.

NAICS code 325412 (Pharmaceutical Preparation Manufacturing) applies. The contract procures 16 line items covering multiple dosage strengths with estimated annual usage volumes ranging from 3,425 to 127,606 units depending on product strength and packaging size. The procurement follows commercial item procedures under FAR Part 12. A modification incorporated Section 5 of Executive Order 14398, Clause 52.222-90, addressing DEI discrimination.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00001 · Modification incorporates section 5 of EO 14398, clause 52.222-90, addressing DEI discrimination. $0
Original award $0

Quick answers

Who was awarded contract 36E79726D0006?

36E79726D0006 was awarded to Sciegen Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on March 2, 2026.

How much is contract 36E79726D0006 worth?

36E79726D0006's own ceiling is $14,500,887.

Who can order from contract 36E79726D0006?

36E79726D0006 is a single award indefinite delivery contract.

Was contract 36E79726D0006 competed?

The extent of competition for 36E79726D0006 was full and open competition. The government received 4 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV